home / stock / bpmuf / bpmuf quote
Last: | $44.45 |
---|---|
Change Percent: | 1.01% |
Open: | $44 |
Close: | $44.45 |
High: | $44.45 |
Low: | $44 |
Volume: | 100 |
Last Trade Date Time: | 04/10/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$44.45 | $44 | $44.45 | $44.45 | $44 | 100 | 04-10-2024 |
$40.75 | $0 | $40.75 | $0 | $0 | 300 | 04-05-2024 |
$40.75 | $40.75 | $40.75 | $40.75 | $40.75 | 5 | 02-13-2024 |
$38.6 | $38.6 | $38.6 | $38.6 | $38.6 | 5 | 01-23-2024 |
$41 | $41 | $41 | $41 | $41 | 7 | 10-18-2023 |
$50 | $50 | $50 | $50 | $50 | 100 | 06-08-2023 |
$50 | $50 | $50 | $50 | $50 | 11 | 05-22-2023 |
$50 | $50 | $50 | $50 | $50 | 10 | 05-19-2023 |
$50 | $50 | $50 | $50 | $50 | 20 | 05-15-2023 |
$52 | $52 | $52 | $52 | $52 | 50 | 11-24-2022 |
$52 | $52 | $52 | $52 | $52 | 50 | 11-23-2022 |
$46 | $46 | $46 | $46 | $46 | 5 | 11-01-2022 |
$41 | $41 | $41 | $41 | $41 | 5 | 09-09-2022 |
$41 | $41 | $41 | $41 | $41 | 40 | 12-13-2021 |
$46 | $46 | $46 | $46 | $46 | 5 | 07-16-2021 |
$49.8048 | $51.2 | $49.8048 | $51.2 | $49.8048 | 100 | 06-21-2021 |
$46.035 | $46.035 | $46.035 | $46.035 | $46.035 | 12 | 05-14-2021 |
$45.05 | $45.05 | $45.05 | $45.05 | $45.05 | 17 | 05-12-2021 |
$51.89 | $51.89 | $51.89 | $51.89 | $51.89 | 100 | 04-21-2021 |
$50.203 | $50.203 | $50.203 | $50.203 | $50.203 | 12 | 04-06-2021 |
News, Short Squeeze, Breakout and More Instantly...
Basilea Pharm Ag Akt Shs Company Name:
BPMUF Stock Symbol:
OTCMKTS Market:
Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combati...
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today th...
Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the an...